Nanoparticles in the Clinic

Overview

Journal Bioeng Transl Med

Date 2018 Jan 10

PMID 29313004

Citations 385

Authors

Aaron C Anselmo

Samir Mitragotri

Affiliations

Soon will be listed here.

Abstract

Nanoparticle/microparticle-based drug delivery systems for systemic (i.e., intravenous) applications have significant advantages over their nonformulated and free drug counterparts. For example, nanoparticle systems are capable of delivering therapeutics and treating areas of the body that other delivery systems cannot reach. As such, nanoparticle drug delivery and imaging systems are one of the most investigated systems in preclinical and clinical settings. Here, we will highlight the diversity of nanoparticle types, the key advantages these systems have over their free drug counterparts, and discuss their overall potential in influencing clinical care. In particular, we will focus on current clinical trials for nanoparticle formulations that have yet to be clinically approved. Additional emphasis will be on clinically approved nanoparticle systems, both for their currently approved indications and their use in active clinical trials. Finally, we will discuss many of the often overlooked biological, technological, and study design challenges that impact the clinical success of nanoparticle delivery systems.

Citing Articles

SynBioNanoDesign: pioneering targeted drug delivery with engineered nanomaterials.

Cai Q, Guo R, Chen D, Deng Z, Gao J J Nanobiotechnology. 2025; 23(1):178.

PMID: 40050980 PMC: 11884119. DOI: 10.1186/s12951-025-03254-9.

Peptide-Coated Nanoparticles for Noninvasive Biomedical Imaging.

Dragulska S, Santiago M, Poursharifi M, Mieszawska A Methods Mol Biol. 2025; 2902:37-53.

PMID: 40029595 DOI: 10.1007/978-1-0716-4402-7_3.

New Nanobioceramics Based on Hydroxyapatite for Biomedical Applications: Stability and Properties.

Ciobanu C, Predoi D, Iconaru S, Negrila C, Leduc D, Ghegoiu L Nanomaterials (Basel). 2025; 15(3).

PMID: 39940201 PMC: 11820604. DOI: 10.3390/nano15030224.

Iron oxide nanoparticles coated with bioactive materials: a viable theragnostic strategy to improve osteosarcoma treatment.

Benjamin A, Nayak S Discov Nano. 2025; 20(1):18.

PMID: 39883285 PMC: 11782756. DOI: 10.1186/s11671-024-04163-w.

Bone-derived nanoparticles (BNPs) enhance osteogenic differentiation Notch signaling.

Stellpflug A, Caron J, Fasciano S, Wang B, Wang S Nanoscale Adv. 2025; 7(3):735-747.

PMID: 39823045 PMC: 11734751. DOI: 10.1039/d4na00797b.

References

Schmidt-Erfurth U, Hasan T . Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol. 2000; 45(3):195-214. DOI: 10.1016/s0039-6257(00)00158-2. View

Thompson K, Goodale D . The recent development of propofol (DIPRIVAN). Intensive Care Med. 2001; 26 Suppl 4:S400-4. DOI: 10.1007/pl00003783. View

Moghimi S, Hunter A, Murray J . Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev. 2001; 53(2):283-318. View

Wang Y, Hussain S, Krestin G . Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol. 2001; 11(11):2319-31. DOI: 10.1007/s003300100908. View

Vogel C, Cobleigh M, Tripathy D, Gutheil J, Harris L, Fehrenbacher L . Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002; 20(3):719-26. DOI: 10.1200/JCO.2002.20.3.719. View

Arap W, Kolonin M, Trepel M, Lahdenranta J, Cardo-Vila M, Giordano R . Steps toward mapping the human vasculature by phage display. Nat Med. 2002; 8(2):121-7. DOI: 10.1038/nm0202-121. View

Otsuka H, Nagasaki Y, Kataoka K . PEGylated nanoparticles for biological and pharmaceutical applications. Adv Drug Deliv Rev. 2003; 55(3):403-19. DOI: 10.1016/s0169-409x(02)00226-0. View

Schutt E, Klein D, Mattrey R, Riess J . Injectable microbubbles as contrast agents for diagnostic ultrasound imaging: the key role of perfluorochemicals. Angew Chem Int Ed Engl. 2003; 42(28):3218-35. DOI: 10.1002/anie.200200550. View

Hirsch L, Stafford R, Bankson J, Sershen S, Rivera B, Price R . Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci U S A. 2003; 100(23):13549-54. PMC: 263851. DOI: 10.1073/pnas.2232479100. View

10.

Leenders F, Mopert K, Schmiedeknecht A, Santel A, Czauderna F, Aleku M . PKN3 is required for malignant prostate cell growth downstream of activated PI 3-kinase. EMBO J. 2004; 23(16):3303-13. PMC: 514518. DOI: 10.1038/sj.emboj.7600345. View

11.

Danielson B . Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol. 2004; 15 Suppl 2:S93-8. DOI: 10.1097/01.ASN.0000143814.49713.C5. View

12.

Gupta A, Gupta M . Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials. 2005; 26(18):3995-4021. DOI: 10.1016/j.biomaterials.2004.10.012. View

13.

Klibanov A . Microbubble contrast agents: targeted ultrasound imaging and ultrasound-assisted drug-delivery applications. Invest Radiol. 2006; 41(3):354-62. DOI: 10.1097/01.rli.0000199292.88189.0f. View

14.

Wagner V, Dullaart A, Bock A, Zweck A . The emerging nanomedicine landscape. Nat Biotechnol. 2006; 24(10):1211-7. DOI: 10.1038/nbt1006-1211. View

15.

Ventura A, Kirsch D, McLaughlin M, Tuveson D, Grimm J, Lintault L . Restoration of p53 function leads to tumour regression in vivo. Nature. 2007; 445(7128):661-5. DOI: 10.1038/nature05541. View

16.

Kelland L . The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007; 7(8):573-84. DOI: 10.1038/nrc2167. View

17.

Sato Y, Murase K, Kato J, Kobune M, Sato T, Kawano Y . Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol. 2008; 26(4):431-42. DOI: 10.1038/nbt1396. View

18.

Akinc A, Zumbuehl A, Goldberg M, Leshchiner E, Busini V, Hossain N . A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol. 2008; 26(5):561-9. PMC: 3014085. DOI: 10.1038/nbt1402. View

19.

McCarthy J, Weissleder R . Multifunctional magnetic nanoparticles for targeted imaging and therapy. Adv Drug Deliv Rev. 2008; 60(11):1241-1251. PMC: 2583936. DOI: 10.1016/j.addr.2008.03.014. View

20.

Dobrovolskaia M, Aggarwal P, Hall J, McNeil S . Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm. 2008; 5(4):487-95. PMC: 2613572. DOI: 10.1021/mp800032f. View